Cleveland Clinic Shaker Heights, OH, United States
Deborah Gold1, Tammy Beckett2, Chad Deal3, Andrew L James4, Jacqueline M Kernaghan5, Mahshid Mohseni6, Abigail McMillan7, Tom Bailey7, Leny Pearman8, John Caminis8, Yamei Wang8 and Setareh A Williams9, 1Duke University Medical Center, Durham, NC, 2Department of Orthopaedics, Orthopaedic Associates of Grand Rapids Research and Education Institute, Grand Rapids, MI, 3Cleveland Clinic, Shaker Heights, OH, 4Columbia Orthopaedic Groups LLP, Columbia, MO, 5Prospect Health Access Network, Springfield, PA, 6Washington University School of Medicine, St. Louis, MO, 7Observational Research Adelphi Real World, Macclesfield, United Kingdom, 8Radius Health, Inc., Waltham, MA, 9CobbsCreek Healthcare, Newtown Square, PA
Background/Purpose: Abaloparatide (ABL) is approved for treatment of women with postmenopausal osteoporosis (PMO) at high risk for fracture. The study evaluated real-world treatment patterns for patients new to ABL regardless of treatment history for osteoporosis (OP).
Methods: This multi-center retrospective study collected data from six academic and clinical practice settings across the US. Patients had to be on ABL for ≥ 1 month prior to enrollment. Follow-up data were collected retrospectively from medical records between December 2020 and August 2021.
Results: A total of 173 patients met the eligibility criteria. Mean age (SD) was 69.8 (7.4) at the time of data collection. Prior to the initiation of ABL, 23.1% reported a fracture, 78.6% of patients had received treatment for OP, of whom 26% had taken teriparatide. The mean (SD) time from discontinuation of an OP medication and initiation of ABL was 20.5 (38.4) months. Over the 24-month follow-up period, 96% of the patients had at least one follow-up visit for management of OP with a median of 3 outpatient consultations. Approximately 24 months of follow-up data since ABL initiation was collected from 94% of patients. Six percent of patients had between 12-24 months of follow-up data. Most patients (55.5%) had access to a medication support program. Patients who completed treatment with ABL received it for a median of 18.6 months with median cumulative exposure to anabolic for 22.5 months. Few patients (5.6%) had gaps in treatment with ABL with a mean (SD) gap of 62.4 (90.5) days. The most common reasons for discontinuation of treatment were financial (11.1%) and adverse events associated with tolerability (8.0%). The observed mean (SD) duration of treatment was longer for patients previously treated for OP compared with those not previously treated 18.0 (8.2) vs. 14.6 (7.3) months. Following treatment with ABL, 51% (n=82) of patients were predominantly prescribed either denosumab (49%, n=40), zoledronic acid (24%, n=20) and teriparatide (11%, n=9). The median time between completion of a course of treatment of ABL and beginning of an OP drug was 21 days, with the maximum time between therapies reported as 12.3 months.
Conclusion: The majority of patients in these clinical settings completed the full course of therapy as prescribed. Consistent with clinical practice guidelines, most patients continued with an antiresorptive. This favorable observed pattern may be a result of the care pathway at these specialized bone health centers, including frequency follow-up visit and accessibility to both medication and patient support services.
Disclosures: D. Gold, Radius Health; T. Beckett, Radius Health; C. Deal, Radius Health, Amgen, Inc., Eli Lilly; A. James, Amgen, Inc; J. Kernaghan, Radius Health, Amgen Inc; M. Mohseni, None; A. McMillan, None; T. Bailey, None; L. Pearman, Radius Health; J. Caminis, Radius Health; Y. Wang, Radius Health; S. Williams, None.
